Buy Mirtazapine

Mirtazapine

Mirtazapine: Generic Medication Overview

Mirtazapine is an antidepressant medication classified within the atypical antidepressants group. It is available in pill form in strengths of 7.5 mg, 15 mg, and 30 mg. In the United Kingdom, mirtazapine is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is marketed under several brand names, most notably Remeron, but the active ingredient is the same across all formulations.

How Mirtazapine Works in the Body

Mirtazapine’s therapeutic effect stems from its mixed pharmacological actions:

• Alpha-2 adrenergic antagonism - blocks presynaptic α2 receptors, leading to increased release of norepinephrine and serotonin.
• Serotonin receptor modulation - strongly antagonises 5-HT₂ and 5-HT₃ receptors while weakly agonising 5-HT₁A receptors, which reduces anxiety-related symptoms and improves sleep.
• Histamine H₁ antagonism - produces the characteristic sedative effect, especially at lower doses.

These actions raise the overall levels of noradrenaline and serotonin in key brain pathways, alleviating depressive symptoms. Oral absorption is good, with peak plasma concentrations reached in 2 - 4 hours. The drug’s half-life averages 20-40 hours, supporting once-daily dosing.

Conditions Treated by Mirtazapine

• Major Depressive Disorder (MDD) - the primary FDA- and MHRA-approved indication.
• Depressive episodes associated with bipolar disorder (as adjunct therapy).
• Anxiety disorders - while not a separate approved indication in the UK, clinicians often prescribe it for depressive-plus-anxiety presentations.

Mirtazapine is generally reserved for patients who have not responded adequately to first-line selective serotonin reuptake inhibitors (SSRIs) or who need a medication with strong sedative properties.

Evidence-Based Off-Label Uses

• Insomnia - due to its H₁ antagonism, low-dose mirtazapine (7.5 mg) is sometimes used off-label to improve sleep quality.
• Appetite stimulation - helpful in patients with cancer-related cachexia or severe unintentional weight loss.
• Post-traumatic stress disorder (PTSD) - limited open-label studies suggest benefit, but it remains off-label.

Disclaimer: Off-label use requires careful medical supervision, assessment of risk-benefit balance, and documentation of informed consent.

Evaluating Mirtazapine for Your Health Profile

Absolute contraindications

• Known hypersensitivity to mirtazapine or any of its excipients.
• Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of stopping an MAOI (risk of serotonin syndrome).

Relative contraindications / cautions

• Pregnancy & lactation - mirtazapine is category B in the UK; use only when the potential benefit outweighs risk.
• Severe hepatic impairment - may increase plasma concentrations; dose reduction recommended.
• Renal insufficiency - mild to moderate renal impairment usually does not require adjustment, but caution in advanced disease.
• Elderly patients - increased sensitivity to sedation and orthostatic hypotension; start at 7.5 mg.

Patients with a history of bipolar disorder should be monitored for emergent mania when initiating therapy.

Safety Profile and Interactions

Common Side Effects

• Sedation / drowsiness (especially after the first few weeks)
• Increased appetite and weight gain
• Dry mouth
• Constipation
• Dizziness (often orthostatic)

These effects are typically mild to moderate and often lessen with continued treatment.

Serious Adverse Events

• Agranulocytosis or neutropenia (rare but potentially life-threatening; monitor complete blood count if clinically indicated).
• Serotonin syndrome - may occur when combined with other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol).
• Suicidal ideation - close monitoring is essential, especially during the initial treatment phase.
• QT interval prolongation - caution in patients with known cardiac conduction disorders or when combined with other QT-prolonging agents.

Drug Interactions

• MAOIs - contraindicated; risk of severe serotonin syndrome.
• SSRIs/SNRIs - may increase serotonin syndrome risk; dose adjustments or close monitoring required.
• CYP1A2, CYP2D6 inhibitors (e.g., fluvoxamine, quinidine) - can raise mirtazapine levels, potentially enhancing sedation.
• CYP inducers (e.g., rifampicin, carbamazepine) - may reduce efficacy.
• Warfarin - limited data; monitor INR if co-prescribed.

Food and Lifestyle Interactions

• Alcohol - potentiates central nervous system depression; advise limiting intake.
• Driving or operating machinery - avoid until you know how mirtazapine affects you, especially during dose initiation.
• No significant food restrictions - can be taken with or without meals.

How to Take Mirtazapine

• Usual starting dose: 15 mg taken once daily, preferably in the evening due to its sedative effect.
• Low-dose initiation: 7.5 mg in the evening may be chosen for patients sensitive to sedation.
• Dose titration: If needed, the dose may be increased by 15 mg increments at intervals of at least 1 week, up to a maximum of 30 mg per day.
• Special populations:
• Elderly: start at 7.5 mg; increase slowly.
• Hepatic impairment: consider starting at 7.5 mg and monitor.
• Administration: Swallow the pill whole with water; food does not affect absorption.
• Missed dose: Take it as soon as you remember unless the next scheduled dose is within a few hours - do not double the dose.
• Overdose: Symptoms may include extreme sedation, respiratory depression, and cardiac arrhythmias. Seek emergency medical care; supportive measures and gastric lavage are typical.
• Discontinuation: Abrupt cessation can lead to rebound insomnia or anxiety. Gradual tapering (e.g., reduce by 7.5 mg every 1-2 weeks) is recommended under medical supervision.

Monitoring and Follow-Up

• Baseline assessment: depression severity scales (e.g., PHQ-9), weight, and blood pressure.
• Early follow-up: within 2 weeks to assess tolerability, especially sedation and mood changes.
• Routine labs: CBC if neutropenia is a concern, liver function tests in hepatic disease, and periodic metabolic panels for weight gain.
• Long-term monitoring: weight, lipid profile, and evaluation for suicidal thoughts throughout treatment.

Storage and Handling

• Keep the pills below 25 °C (77 °F), in a dry place away from direct sunlight.
• Store in the original container to protect from moisture.
• Keep out of reach of children and pets.
• Do not use medication past the expiry date printed on the package; discard according to local pharmacy guidelines.

Medication-Specific Glossary

Alpha-2 adrenergic antagonist

A drug that blocks presynaptic α2 receptors, increasing the release of norepinephrine and serotonin.

Serotonin syndrome

A potentially life-threatening condition caused by excess serotonergic activity, presenting with agitation, hyperthermia, tremor, and autonomic instability.

QT interval prolongation

Lengthening of the heart’s electrical repolarisation phase, which can predispose to a dangerous arrhythmia called torsades de pointes.

Agranulocytosis

A severe drop in white blood cell count (neutrophils), raising infection risk; a rare but serious side effect of some antipsychotics and antidepressants.

H₁ antihistamine effect

Blockade of histamine H₁ receptors, leading to sedation and appetite stimulation.

Medical Disclaimer

This article provides educational information about Mirtazapine and is not a substitute for professional medical advice. Treatment decisions, including the use of off-label indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.